To read the full story, subscribe or sign in.

Celgene invests in Mesoblast and gains option to license cancer and inflammation cell therapies

April 13, 2015

BioWorld Science Other news to note Collaboration

Today's news in brief

BioWorld

BioWorld briefs for April 28, 2026.

News in brief

BioWorld Asia

BioWorld Asia briefs for April 28, 2026

Grace Therapeutics hits CRL setback with GTx-104 despite positive trial

BioWorld

Grace Therapeutics Inc.’s hopes of becoming the first company in decades to update the standard of care in aneurysmal subarachnoid hemorrhage were delayed after...

Epileptic brain and abnormal EEG wave discharges

Neuro deals aplenty: UCB’s $1B+ takeover of Neurona the latest

BioWorld

A flurry of deals focused on the neurological disease space in 2026 suggest large biopharma companies are searching for the next best therapeutics for everything...

Pleased to own ya, Kelonia: Lilly’s $7B CAR T deal

BioWorld

The already-thriving CAR T space took another big stride forward as Eli Lilly and Co. disclosed its plan to acquire Boston-based Kelonia Therapeutics Inc. for as...